Eikon Therapeutics, a Hayward, CA-based pivotal-stage biotechnology company for drug discovery and development, raised $350.7M in Series D funding.
The investment syndicate was composed of mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others. Since its founding in 2019, Eikon Therapeutics has raised in excess of $1.1 billion.
Led by Roger M. Perlmutter, M.D., Ph.D., and CEO, Eikon Therapeutics is advancing therapies through the integration of science and engineering. Its proprietary discovery technologies leverage super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness.
The company intends to use the funds to expand operations and its R&D efforts. Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. EIK1001 has demonstrated both single-agent efficacy and promising in-combination activity with anti-PD-(L)1 agents across multiple tumor types. In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers. Its early-stage pipeline features, among other undisclosed candidates, two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its potential as a therapy for patients with MSI-high and other DNA repair–deficient cancers.
The company operates from its facilities in California, New Jersey, and New York.
FinSMEs
27/02/2025